Core Heavyweights
Tirzepatide is a dual incretin agonist targeting both the GIP and GLP-1 receptors. PX1 Research manufactures tirzepatide domestically under cGMP-compliant controls with full analytical release testing.
Tirzepatide binds the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The combined signalling profile is the basis for the compound's distinct research interest versus single-agonist GLP-1 analogs.
The SURPASS clinical program (including SURPASS-2, a head-to-head comparison against semaglutide) is the primary published body of evidence describing tirzepatide's dual-agonist pharmacology. All PX1 material is supplied strictly for laboratory research use.
Use the reconstitution calculator to convert vial strength and solvent volume into exact insulin-syringe unit marks before you begin a protocol.
Convert vial strength and bacteriostatic water volume into exact insulin-syringe unit marks.
Peptide reconstitution calculator
Concentration
5 mg/mL
Draw volume
0.05 mL
Insulin syringe
5 units (IU)
U-100 insulin syringe (100 units = 1 mL)
10 mg + 2 mL = 5 mg/mL. A 250 mcg dose = 5 units on a U-100 syringe (40 doses per vial).
For laboratory and research use only. Not for human or veterinary use.
Need solvent? Buy bacteriostatic water (10mL / 30mL)
Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds a third target, the glucagon receptor, making it a triple agonist.
Add bacteriostatic water to the lyophilized vial along the glass wall, swirl gently without shaking, and refrigerate at 2–8°C once dissolved.
